MX2024010527A - Terapia de células car-t dirigida a bcma para mieloma múltiple - Google Patents

Terapia de células car-t dirigida a bcma para mieloma múltiple

Info

Publication number
MX2024010527A
MX2024010527A MX2024010527A MX2024010527A MX2024010527A MX 2024010527 A MX2024010527 A MX 2024010527A MX 2024010527 A MX2024010527 A MX 2024010527A MX 2024010527 A MX2024010527 A MX 2024010527A MX 2024010527 A MX2024010527 A MX 2024010527A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
bcma
cell therapy
ciltacabtagene
autoleucel
Prior art date
Application number
MX2024010527A
Other languages
English (en)
Spanish (es)
Inventor
Xiaohu Fan
Jordan Schecter
Lida Pacaud
Michael Hirschmann
Original Assignee
Janssen Biotech Inc
Nanjing Legend Biotech Co Ltd
Legend Biotech Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Nanjing Legend Biotech Co Ltd, Legend Biotech Usa Inc filed Critical Janssen Biotech Inc
Publication of MX2024010527A publication Critical patent/MX2024010527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
MX2024010527A 2022-02-28 2024-08-27 Terapia de células car-t dirigida a bcma para mieloma múltiple MX2024010527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263314968P 2022-02-28 2022-02-28
PCT/US2023/063352 WO2023164695A2 (en) 2022-02-28 2023-02-27 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (1)

Publication Number Publication Date
MX2024010527A true MX2024010527A (es) 2024-12-06

Family

ID=87762032

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010527A MX2024010527A (es) 2022-02-28 2024-08-27 Terapia de células car-t dirigida a bcma para mieloma múltiple

Country Status (9)

Country Link
US (1) US20230270786A1 (enExample)
EP (1) EP4486372A2 (enExample)
JP (1) JP2025507678A (enExample)
KR (1) KR20240158888A (enExample)
CN (1) CN118900698A (enExample)
AU (1) AU2023223523A1 (enExample)
CA (1) CA3252674A1 (enExample)
MX (1) MX2024010527A (enExample)
WO (1) WO2023164695A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929747A (zh) 2019-11-05 2022-08-19 詹森生物科技公司 多发性骨髓瘤的靶向bcma的car-t细胞疗法
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
WO2025170902A1 (en) * 2024-02-05 2025-08-14 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
US20250339527A1 (en) * 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR102512934B1 (ko) 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법

Also Published As

Publication number Publication date
CN118900698A (zh) 2024-11-05
EP4486372A2 (en) 2025-01-08
US20230270786A1 (en) 2023-08-31
AU2023223523A1 (en) 2024-09-26
WO2023164695A3 (en) 2023-10-05
WO2023164695A2 (en) 2023-08-31
KR20240158888A (ko) 2024-11-05
CA3252674A1 (en) 2023-08-31
JP2025507678A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
CL2023001293A1 (es) Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado
MX2020014119A (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
CL2020000681A1 (es) Segmento de barra de material generador de aerosol.
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
USD902427S1 (en) Ejaculation promotion apparatus
MX370511B (es) Herramienta o parte de herramienta, sistema que incluye dicha herramienta o parte de herramienta, método para producir dicha herramienta o parte de herramienta y método para moldear un producto a partir de una suspensión de pulpa.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2022014642A (es) Lentes oftalmicas, metodos de fabricacion de lentes oftalmicas y metodos de dispensacion de productos para el cuidado de los ojos, incluidos los mismos.
WO2023164695A3 (en) Bcma-targeted car-t cell therapy for multiple myeloma
MX2017016289A (es) Mutaciones de la enzima crispr que reducen los efectos fuera del blanco.
PE20221563A1 (es) Metodo y sistema para rastrear envases
BR112015015582A2 (pt) aparelho e método
MX2023005997A (es) Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion.
MX2020002957A (es) Productos topicos con un sistema bifasico.
MX2022007019A (es) Producto oral que contiene un canabinoide.
CO5700832A2 (es) Suspensiones acuosas de ciclesonide para nebulizacion
CL2020001050A1 (es) Un filtro para un artículo para fumar o un producto generador de aerosol.
WO2023164544A3 (en) Novel ionizable cationic lipids
CO2020002156A2 (es) Produccion a gran escala de productos líquidos y solidos de trichoderma
BR112022018578A2 (pt) Métodos para fornecer um produto de hmo sólido e produtos de hmo sólido obtidos por meio deles
ES2107430T3 (es) Procedimiento para preparar complejos de piroxicam/ciclodextrina, los productos obtenidos y sus composiciones farmaceuticas.
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
EP3978660A4 (en) STRUCTURAL PROTEIN MICROBODY AND METHOD FOR PRODUCTION THEREOF, NANOFIBER PRODUCTION METHOD AND PROTEIN STRUCTURE PRODUCTION METHOD
CL2022001417A1 (es) Proceso para los productos de sintegas.
DOP2026000045A (es) Envases asépticos reciclables y métodos relacionados